Atopic DermatitisNCT07067541
Clinical Observation of Topical Lidocaine Cream Combined With Moisturizing Cream in the Treatment of Atopic Dermatitis
A study testing Experimental lidocaine cream + moisturizer cream in people with Atopic Dermatitis, run by First Affiliated Hospital of Kunming Medical University at 1 site in China.
Trial summary
Twenty-five patients with atopic dermatitis applied lidocaine cream plus a moisturizer to the right limb and lidocaine cream alone to the left limb, twice daily for four weeks. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Atopic Dermatitis
- What is being tested?
- Experimental lidocaine cream + moisturizer cream
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2023to 31 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female patients aged 18-65 years.
- Clinical diagnosis of atopic dermatitis according to the 2020 Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China (symmetrical eczematous lesions for ≥6 months plus personal/family atopy history or elevated IgE/eosinophilia).
- Voluntarily signed informed consent form.
Who cannot join
- Active heart, liver, kidney, or other serious systemic illness.
- History of viral or bacterial infection within 1 month prior to enrollment.
- Immunocompromised patients or those receiving systemic immunosuppressive therapy.
- Known allergy to lidocaine, moisturizer components, or any study-related topical agents.
- Pregnant or breastfeeding women.
- Use of topical corticosteroids or calcineurin inhibitors within 2 weeks prior to enrollment.
Trial locations and contacts
1 site in 1 country.
China1 site
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650000
About this study
Twenty-five patients with atopic dermatitis applied lidocaine cream plus a moisturizer to the right limb and lidocaine cream alone to the left limb, twice daily for four weeks.
- Conditions
- Atopic Dermatitis
- Being tested
- Control lidocaine cream, Experimental lidocaine cream + moisturizer cream
- Medical subject headings
- Dermatitis, Atopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Control lidocaine creamDrug
lidocaine cream alone
Experimental lidocaine cream + moisturizer creamDrug
lidocaine cream + moisturizer cream
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Active comparator | Not described Receives: Drug: Control lidocaine cream |
| Experimental group | Experimental | Not described Receives: Drug: Experimental lidocaine cream + moisturizer cream |
What is being measured
The primary outcome is the main question the study is designed to answer.
change in SCORAD (SCORing Atopic Dermatitis) from baseline
For each patient, a score will be obtained at baseline, after 4 weeks. The minimum score is 0 (best outcome) and the maximum score is 103 (worst outcome).
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start1 Oct 2023
- Primary completion31 Jan 2024
- Study completion31 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Kunming Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tang Junting, First Affiliated Hospital of Kunming Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07067541
- Sponsor's protocol ID
- 2023-L-88
- Status last verified
- Jul 2025
- First submitted
- 1 Jul 2025
- Last updated
- 16 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Observation of Topical Lidocaine Cream Combined With Moisturizing Cream in the Treatment of Atopic Dermatitis
- ClinicalTrials.gov ID
- NCT07067541
- Acronym / sponsor ID
- 2023-L-88
- Conditions
- Atopic Dermatitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- First Affiliated Hospital of Kunming Medical UniversityUniversity, hospital or other
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 31 Jan 2024 (actual)
- Study completion
- 31 Jan 2024 (actual)
- First posted
- 16 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Twenty-five patients with atopic dermatitis applied lidocaine cream plus a moisturizer to the right limb and lidocaine cream alone to the left limb, twice daily for four weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Group | Active comparator | Drug: Control lidocaine cream |
| Experimental group | Experimental | Drug: Experimental lidocaine cream + moisturizer cream |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Male or female patients aged 18-65 years.
- Clinical diagnosis of atopic dermatitis according to the 2020 Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China (symmetrical eczematous lesions for ≥6 months plus personal/family atopy history or elevated IgE/eosinophilia).
- Voluntarily signed informed consent form.
Key exclusion criteria (6 listed)
- Active heart, liver, kidney, or other serious systemic illness.
- History of viral or bacterial infection within 1 month prior to enrollment.
- Immunocompromised patients or those receiving systemic immunosuppressive therapy.
- Known allergy to lidocaine, moisturizer components, or any study-related topical agents.
- Pregnant or breastfeeding women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Control lidocaine creamlidocaine cream alone | Drug | Control Group |
| Experimental lidocaine cream + moisturizer creamlidocaine cream + moisturizer cream | Drug | Experimental group |
Primary outcome
change in SCORAD (SCORing Atopic Dermatitis) from baseline
Time frame: 4 weeks
For each patient, a score will be obtained at baseline, after 4 weeks. The minimum score is 0 (best outcome) and the maximum score is 103 (worst outcome).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2025.
Related trials for Atopic Dermatitis
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental lidocaine cream + moisturizer cream in people with Atopic Dermatitis, run by First Affiliated Hospital of Kunming Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change in SCORAD (SCORing Atopic Dermatitis) from baseline (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2025.